On 12 November 2026, Lupin and Sandoz announced the launch of Ranluspec®, biosimilar to Genentech’s Lucentis® (ranibizumab), in Europe, excluding Germany. Ranluspec® is developed, manufactured and registered by Lupin and is commercialised by Sandoz in the EU (excluding Germany) under an August 2025 agreement.
Ranluspec® was approved by the European Commission in February 2026 in vial and pre-filled syringe presentations and is indicated for the treatment of nAMD, visual impairment due to DME, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to retinal vein occlusion (RVO) and visual impairment due to choroidal neovascularisation.
Ranibizumab biosimilars already approved and launched in Europe include Samsung Bioepis’ Byooviz® (approved August 2021, commercially available since March 2023), STADA/Xbrane’s Ximluci® (launched in April 2023, following November 2022 approval), and Formycon’s Ranivisio® (approved August 2022, commercialised in by Teva). Lupin’s Vislyfa® (ranibizumab) was recommended by the CHMP in May 2026 and approved in July 2026, while Accord’s Fovlussea® and Intas’ Rexatilux® received positive CHMP opinions in October 2026 and April 2026 (approved June 2026), respectively.
